DNER and diffuse large B-cell lymphoma: At least four small-molecule bromodomain inhibitors of BET are in ongoing oncology/hematology early phase I clinical studies (CPI-0610, NCT01949883; GSK525762, NCT01587703; OTX015, NCT01713582 and TEN-010, NCT01987362), which include relapsed/refractory DLBCL (CPI-0610; NCT01949883) (Additional file 1: Table S2).